Newsroom & Stories

NEWSROOM

News & Stories

Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?
How these tests can help create a treatment plan that’s right for you Navigating Your Diagnosis Being diagnosed with early-stage breast cancer can feel overwhelming. You’re asked to make important Read More
Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and Read More
The Endocrine System and Breast Cancer Overview
The endocrine system is a series of glands responsible for creating and distributing hormones throughout the body, chemical messengers of sorts. This important system plays a role in many Read More

Newsroom

Press Releases

Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

Joel Adamich2023-06-18T21:17:25-04:00

At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer.

Read More

Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

Joel Adamich2024-08-15T13:25:16-04:00

Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendia’s progress in developing practice-changing evidence to improve personalized cancer care Read More

Updated NCCN^® Guidelines Recognize MammaPrint^® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates

Joel Adamich2024-11-01T13:50:34-04:00

Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapy¹ and endocrine therapy² Conﬁrms Agendia’s unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More

Previous 91011 Next

Newsroom

News, Stories & Breast Cancer Blog

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

View Our Video

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

View the data

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View the portrait series

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.

Cookie	Duration	Description
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Cookie	Duration	Description
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

NEWSROOM

Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?

Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough

The Endocrine System and Breast Cancer Overview

Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?

Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough

The Endocrine System and Breast Cancer Overview

Newsroom

Press Releases

Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

Updated NCCN^® Guidelines Recognize MammaPrint^® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates

Newsroom

News, Stories & Breast Cancer Blog

RON KALFUS

STEPHANIE BYWATER